1. Home
  2. HURN vs CELC Comparison

HURN vs CELC Comparison

Compare HURN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huron Consulting Group Inc.

HURN

Huron Consulting Group Inc.

HOLD

Current Price

$179.87

Market Cap

2.8B

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$102.02

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HURN
CELC
Founded
2002
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.1B
IPO Year
2004
2017

Fundamental Metrics

Financial Performance
Metric
HURN
CELC
Price
$179.87
$102.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$199.00
$100.13
AVG Volume (30 Days)
130.3K
870.9K
Earning Date
10-28-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
32.32
N/A
EPS
5.98
N/A
Revenue
$1,618,977,000.00
N/A
Revenue This Year
$14.19
N/A
Revenue Next Year
$9.49
N/A
P/E Ratio
$30.20
N/A
Revenue Growth
12.67
N/A
52 Week Low
$120.25
$7.58
52 Week High
$182.71
$112.64

Technical Indicators

Market Signals
Indicator
HURN
CELC
Relative Strength Index (RSI) 68.39 59.89
Support Level $178.00 $97.27
Resistance Level $181.14 $103.50
Average True Range (ATR) 4.82 4.47
MACD -0.02 -1.13
Stochastic Oscillator 90.91 31.23

Price Performance

Historical Comparison
HURN
CELC

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: